Journal
KIDNEY INTERNATIONAL
Volume 96, Issue 3, Pages 593-596Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2019.03.006
Keywords
artificial pancreas; closed-loop insulin delivery; glucose control; hemodialysis
Categories
Funding
- Diabetes UK [14/0004878]
- Swiss National Science Foundation [P1BEP3_165297]
- European Foundation for the Study of Diabetes
- JDRF by the National Institute for Health Research Cambridge Biomedical Research Centre
- Wellcome Strategic Award [100574/Z/12/Z]
- University Hospital Bern
- Swiss Diabetes Foundation
- Fonds pour la recherche therapeutique (funds for therapeutic research) Pully, Switzerland
- Inselspital, Bern University Hospital, Bern
- University of Bern
- Swiss National Science Foundation (SNF) [P1BEP3_165297] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Inpatient diabetes management of those on hemodialysis poses a major challenge. In a post hoc analysis of a randomized controlled clinical trial, we compared the efficacy of fully automated closed-loop insulin delivery vs. usual care in patients undergoing hemodialysis while in hospital. Compared to control patients receiving conventional subcutaneous insulin therapy, those patients receiving closed-loop insulin delivery significantly increased the proportion of time when a continuous glucose monitor was in the target range of 5.6-10.0 mmol/l by 37.6 percent without increasing the risk of hypoglycemia. Thus, closed-loop insulin delivery offers a novel way to achieve effective and safe glucose control in this vulnerable patient population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available